Regular injections can help strengthen your bodys defenses, especially during the colder months
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease
2026 UK review of synaptic loss, the BDNF/HGF axis, the NICE lecanemab/donanemab rejection & Read the full review Sleep, Circadian, Injury & Neuro-Rehab Sleep and body-clock disruption, and recovery after injury, treatment or sensory damage
We retest your labs